KURA
Kura Oncology, Inc. (NASDAQ)
Healthcare — Biotechnology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $956.99M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.15 |
| EPS (TTM) | $-3.35 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 29.50% |
| ROE | -124.74% |
| Debt/Equity | 22.50 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $31.17 |
| Analysts | 12 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 82.0 |
| Beta | 0.36 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $12.49 |
| 52-Week Low | $5.45 |
| 50-Day Avg | $9.60 |
| 200-Day Avg | $9.46 |
| Avg Volume | $1.70M |
| Volume | $2.06M |
Performance Analysis
BULLISHKURA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:17 UTC
Back to Screener Export Report